Hyperbare Sauerstofftherapie bei arteriellen Gefäßverschlüssen der Netzhaut

Aisenbrey, Sabine; Krott, Ralf; Heller, Rainer; Krauss, Denise; Rössler, Gernot; Heimann, Klaus

doi:10.1007/s003470070075

Cited by 35 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the remaining 80 articles, 73 articles were removed due to being case reports (n = 22), being reviews (n = 8), not being an RCT (n = 24), or not reporting relevant outcomes (n = 19). Seven studies were finally included in this meta-analysis [ 22 – 28 ].Three studies were published in English [ 23 – 25 ], three studies were published in Chinese [ 26 – 28 ], and one study was published in German [ 22 ]. ( Table 1 ) showed the main characteristics of the 7 studies.…”

Section: Resultsmentioning

confidence: 99%

Oxygen therapy in patients with retinal artery occlusion: A meta-analysis

Xiao-dong

Chen

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

BackgroundOxygen therapy has been widely used for RAO (retinal artery occlusion) patients; however, inconsistent results have been reported.MethodsPubMed, Web of Science, EMBASE, Medline (OvidSP), Cochrane, China National Knowledge Infrastructure (CNKI), and Wanfang Database were examined. The primary endpoint was visual acuity (VA), and RevMan software 5.3 was used to statistically analyze the outcomes.ResultsSeven randomized controlled trials (RCTs) met the inclusion criteria. Patients who received oxygen therapy exhibited probability of visual improvement about 5.61 times compared with the control group who did not receive oxygen therapy (OR = 5.61; 95% CI, 3.60–8.73; p < 0.01). No statistically significant difference was observed between oxygen inhalation methods (Chi2 = 0.18, df = 1, p = 0.67), combined therapy (Chi2 = 0.21, df = 1, p = 0.64), or RAO type (Chi2 = 0.06, df = 1, p = 0.81). Conversely, 100% oxygen (Chi2 = 4.55, df = 1, p < 0.05) and hyperbaric oxygen (Chi2 = 4.55, df = 1, p < 0.05) significantly improved VA in RAO patients. Better effect was showed in period within 3 months (Chi2 = 5.76, df = 1, p < 0.05). The most effective treatment length was over 9 hours (Chi2 = 6.58, df = 1, p < 0.05).ConclusionOxygen therapy demonstrated beneficial effects in improving VA in RAO patients, particularly when patients were treated with 100% hyperbaric oxygen and for over 9 hours.

show abstract

Section: Resultsmentioning

confidence: 99%

Oxygen therapy in patients with retinal artery occlusion: A meta-analysis

Xiao-dong

Chen

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The alternatives for the treatment of CRAO in SCD consist of pharmacological and mechanical reduction of ocular pressure, HBO therapy, ocular massage, and direct thrombolysis, however their benefits are not well proven [ 6 ]. HBO therapy was reported to be useful in the treatment of CRAO [ 8 - 11 ]. This therapy shows its effect by increasing tissue oxygenation.…”

Section: Discussionmentioning

confidence: 99%

Hyperbaric oxygen therapy in combination with systemic treatment of sickle cell disease presenting as central retinal artery occlusion: a case report

2014

View full text Add to dashboard Cite

IntroductionWe describe hyperbaric oxygen therapy for the treatment of central retinal artery occlusion in a young adult with sickle cell disease.Case presentationA 25-year-old Turkish man with a history of sickle cell disease developed sudden painless loss of vision in the left eye and was hospitalized for diagnosis and treatment. Central retinal artery occlusion was diagnosed with retinal whitening, cherry red spot, and delayed arteriovenous transit on fluorescein angiography. He underwent exchange transfusion and hyperbaric oxygen therapy. In the following three months, his visual acuity improved to 20/30.ConclusionsIn this present case with sickle cell disease, the visual acuity improved with hyperbaric oxygen therapy in addition to systemic therapy. The result of our case suggests that hyperbaric oxygen therapy may be beneficial in the treatment of central retinal artery occlusion.

show abstract

“…The exact pathogenesis is debated [41, 42, 43•, 44–46] and the efficacy is not proven. The protocol for hyperbaric oxygen varies in different studies, with an average of 2–2.5 atm for approximately 90 min within 8 h of onset of CRAO [47].…”

Section: Treatmentmentioning

confidence: 99%

Treatment Options for Central Retinal Artery Occlusion

Cugati

Varma

Chen

et al. 2012

Curr Treat Options Neurol

145

121

View full text Add to dashboard Cite

Opinion statementCentral retinal artery occlusion (CRAO) is an ocular emergency and is the ocular analogue of cerebral stroke. It results in profound, usually monocular vision loss, and is associated with significant functional morbidity. The risk factors for CRAO are the same atherosclerotic risk factors as for stroke and heart disease. As such, individuals with CRAO may be at risk of ischemic end organ damage such as a cerebral stroke. Therefore, the management of CRAO is not only to restore vision, but at the same time to manage risk factors that may lead to other vascular conditions. There are a number of therapies that has been used in the treatment of CRAO in the past. These include carbogen inhalation, acetazolamide infusion, ocular massage and paracentesis, as well as various vasodilators such as intravenous glyceryl trinitrate. None of these “standard agents” have been shown to alter the natural history of disease definitively. There has been recent interest shown in the use of thrombolytic therapy, delivered either intravenously or intra-arterially by direct catheterisation of the ophthalmic artery. Whilst a number of observational series have shown that the recovery of vision can be quite dramatic, two recent randomised controlled trials have not demonstrated efficacy. On the contrary, intra-arterial delivery of thrombolytic may result in an increased risk of intracranial and systemic haemorrhage, while the intravenous use of tissue plasminogen activator (tPA) was not shown to be efficacious within 24 h of symptom onset. Nevertheless, both of these studies have shown one thing in common, and that is for treatment to be effective in CRAO, it must be deployed within a short time window, probably within 6 h of symptom onset. Therefore, while CRAO is a disease that does not have a treatment, nevertheless it needs to follow the same principles of treatment as any other vascular end organ ischaemic disease. That is, to attempt to reperfuse ischemic tissue as quickly as possible and to institute secondary prevention early.

show abstract

Hyperbare Sauerstofftherapie bei arteriellen Gefäßverschlüssen der Netzhaut

Abstract: HBO seems to be beneficial for VA in eyes with BRAO. Further investigations are necessary to prove this observation.

Cited by 35 publications

References 23 publications

Oxygen therapy in patients with retinal artery occlusion: A meta-analysis

Oxygen therapy in patients with retinal artery occlusion: A meta-analysis

Hyperbaric oxygen therapy in combination with systemic treatment of sickle cell disease presenting as central retinal artery occlusion: a case report

Treatment Options for Central Retinal Artery Occlusion

Contact Info

Product

Resources

About